ICON Acquires Veeda Laboratories

Thursday, July 9, 2009 08:03 AM

Dublin, Ireland-based contract research organization ICON acquired Veeda Laboratories, a provider of biomarker laboratory services for an undisclosed sum.

The acquisition is intended to bulk up ICON's existing bioanalytical and immunoassay capabilities, which are based at a laboratory in Manchester, UK, and Prevalere Life Sciences, the U.S. lab acquired by ICON last November.

"Biomarkers of disease are assuming an ever increasing role in the discovery and development of drugs," said ICON Development Solutions president Thomas Frey in a company statement. "In Veeda Laboratories, we have acquired a company that has a very strong reputation for biomarker development and has well-established relationships with top-tier pharmaceutical and biotechnology companies. Veeda's team of scientists will also greatly enhance ICON's existing team of biomarker experts."

Veeda Laboratories is a wholly-owned subsidiary of Veeda Clinical Research Group.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs